BONE MARROW TRANSPLANTATION

Scope & Guideline

Innovating Hematology: Pioneering Bone Marrow Research.

Introduction

Immerse yourself in the scholarly insights of BONE MARROW TRANSPLANTATION with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN0268-3369
PublisherSPRINGERNATURE
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1986 to 2024
AbbreviationBONE MARROW TRANSPL / Bone Marrow Transplant.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressCAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND

Aims and Scopes

The journal 'BONE MARROW TRANSPLANTATION' focuses on the latest advancements and research findings in the field of hematopoietic stem cell transplantation (HSCT) and related cellular therapies. It encompasses a wide range of studies, from clinical trials to epidemiological analyses, aiming to improve the understanding and treatment of hematological malignancies and other disorders through transplantation.
  1. Hematopoietic Stem Cell Transplantation (HSCT):
    The journal emphasizes research on the efficacy, safety, and outcomes of HSCT for various hematological disorders, including leukemia, lymphoma, and myelodysplastic syndromes. This encompasses studies on conditioning regimens, donor selection, and post-transplant care.
  2. Graft-versus-Host Disease (GVHD):
    A significant part of the journal's focus is on the prevention, diagnosis, and treatment of GVHD, a common complication following HSCT. This includes exploring novel prophylactic strategies and therapies for managing acute and chronic GVHD.
  3. Innovative Therapies and Techniques:
    Research on novel cellular therapies such as CAR-T cell therapy, as well as advancements in immunotherapy and targeted therapies, is frequently published, reflecting the journal's commitment to integrating new treatment modalities into clinical practice.
  4. Infectious Complications and Management:
    The journal addresses the challenges of infectious complications in HSCT recipients, including the management of viral reactivations (e.g., CMV, EBV) and bacterial infections, highlighting the importance of prophylactic strategies and treatment protocols.
  5. Patient-Centered Care and Quality of Life:
    Studies examining the psychosocial aspects, quality of life, and long-term outcomes of patients undergoing HSCT are also a critical focus, emphasizing the holistic approach to patient care.
The journal reflects ongoing advancements and shifts in research focus, with several emerging themes gaining attention. These trends indicate the evolving landscape of hematopoietic stem cell transplantation and associated therapies.
  1. Post-Transplant Cyclophosphamide (PTCy):
    There is a growing body of research dedicated to the use of PTCy as a prophylactic treatment in haploidentical stem cell transplantation, highlighting its effectiveness in reducing GVHD and improving transplant outcomes.
  2. CAR-T Cell Therapy:
    The ongoing exploration of CAR-T cell therapy in various hematological malignancies, particularly in relapsed or refractory cases, is a prominent theme, showcasing its integration into transplantation protocols.
  3. Patient Engagement and Quality of Life Research:
    An increasing focus on patient-reported outcomes and quality of life in HSCT recipients signifies a shift towards more patient-centered research, emphasizing the importance of psychosocial factors in treatment success.
  4. Microbiome Research in Transplantation:
    Emerging studies investigating the role of gut microbiota in transplant outcomes and GVHD are gaining traction, reflecting a broader interest in the interplay between microbiome health and patient recovery.
  5. Use of Advanced Imaging and Biomarkers:
    The integration of advanced imaging techniques and biomarker research to predict outcomes post-transplantation is becoming more common, enhancing the ability to tailor treatments to individual patient needs.

Declining or Waning

While 'BONE MARROW TRANSPLANTATION' continues to evolve, certain themes and areas of research are witnessing a decline in prominence. This may reflect shifts in clinical priorities, emerging treatments, or changes in the scientific landscape.
  1. Traditional Conditioning Regimens:
    There is a noticeable decrease in studies focused solely on traditional myeloablative conditioning regimens as researchers increasingly explore reduced-intensity and non-myeloablative approaches, which are becoming more favored in practice.
  2. Single Donor Transplantation Studies:
    Research focusing on single donor transplantation models, particularly in less diverse donor settings, is becoming less common as the field shifts towards exploring haploidentical and mismatched donor strategies, which are gaining traction.
  3. Basic Science Studies on Stem Cell Biology:
    There seems to be a waning interest in basic science research solely focused on stem cell biology without direct clinical applications, as more research is geared towards translational studies and clinical outcomes.
  4. Longitudinal Studies with Limited Sample Sizes:
    The frequency of longitudinal studies with small sample sizes appears to be decreasing, as there is a growing emphasis on larger, multicenter studies that offer more robust data and generalizable findings.

Similar Journals

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Leading the Way in Clinical Hematology Research
Publisher: ELSEVIER SCI LTDISSN: 1521-6926Frequency: 4 issues/year

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY is a leading academic journal published by ELSEVIER SCI LTD, dedicated to advancing knowledge in the field of clinical hematology. Since its inception in 1999, the journal has provided a platform for high-quality research, offering insights that bridge the gap between clinical practice and breakthrough scientific discoveries. With its significant standing, the journal has garnered a Q2 ranking in both Clinical Biochemistry and Oncology as of 2023, indicating its influence and authority within these domains. Although it does not operate under an open-access model, BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY remains essential for researchers, healthcare professionals, and students looking to stay informed about the latest developments in hematological science. The journal's rigorous peer-review process and commitment to publishing innovative studies make it a cornerstone resource for anyone invested in clinical hematology and related fields.

INTERNATIONAL JOURNAL OF HEMATOLOGY

Elevating Hematology Research to New Heights
Publisher: SPRINGER JAPAN KKISSN: 0925-5710Frequency: 12 issues/year

The INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.

Experimental Hematology & Oncology

Pioneering Insights in Hematology and Oncology
Publisher: BMCISSN: Frequency: 1 issue/year

Experimental Hematology & Oncology is a premier journal published by BMC, dedicated to advancing knowledge in the fields of hematology, oncology, and cancer research. Since its inception in 2012, this Open Access journal has emerged as a vital resource for researchers and healthcare professionals, fostering the dissemination of high-quality research that enhances our understanding of blood disorders and malignancies. With impressive rankings in Quarters 1 of key categories including Cancer Research, Hematology, and Oncology, it holds significant prestige, evidenced by its Scopus rankings: #42/404 in Medicine (Oncology) and #17/137 in Medicine (Hematology). The journal aims to publish cutting-edge studies, reviews, and perspectives that contribute to the evolution of therapeutic strategies and innovative treatment modalities. Researchers and practitioners alike will find this journal indispensable for staying at the forefront of breakthroughs in hematological and oncological research.

AMERICAN JOURNAL OF HEMATOLOGY

Connecting Scholars to Shape the Future of Hematology
Publisher: WILEYISSN: 0361-8609Frequency: 12 issues/year

American Journal of Hematology, published by Wiley, stands as a premier outlet for the dissemination of cutting-edge research in the field of hematology. With a commendable impact factor and ranked #9 out of 137 in the Scopus medicine category, this journal has established a robust presence since its inception in 1976. Operating in the Q1 quartile for hematology, it serves as a crucial resource for researchers, clinicians, and students dedicated to understanding blood disorders and advancing treatment methodologies. While the journal does not currently offer open access options, it remains highly regarded for its rigorous peer-review process and impactful contributions to the scientific community. With coverage extending into 2024, the American Journal of Hematology is committed to fostering innovation and collaboration within the hematological sciences.

Egyptian Journal of Haematology

Unveiling Innovations in Hematologic Research
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 1110-1067Frequency: 4 issues/year

The Egyptian Journal of Haematology, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of hematology, particularly within the context of Egypt and the broader Middle Eastern region. This journal is dedicated to disseminating high-quality research that explores the latest advancements in blood disorders, hematologic malignancies, and transfusion medicine. With a focus on original research, case studies, and reviews, it aims to provide a comprehensive platform for hematologists, researchers, and healthcare professionals to enhance their understanding and management of hematological conditions. Although it is not an open-access journal, the rigorous peer-review process ensures that only the most impactful studies are published, contributing to the journal's reputation in the academic community. The Egyptian Journal of Haematology serves as an essential tool for advancing knowledge, improving clinical outcomes, and fostering collaboration among experts in the field.

JOURNAL OF CLINICAL IMMUNOLOGY

Advancing the Frontiers of Immune Research
Publisher: SPRINGER/PLENUM PUBLISHERSISSN: 0271-9142Frequency: 8 issues/year

JOURNAL OF CLINICAL IMMUNOLOGY, published by SPRINGER/PLENUM PUBLISHERS, is a leading journal in the field of immunology, with an impressive standing as reflected in its Q1 ranking in both Immunology and Immunology and Allergy for 2023. With a history of publication dating back to 1981 and an E-ISSN of 1573-2592, this journal aims to disseminate cutting-edge research on diagnostic methods, therapeutic strategies, and understanding the mechanisms underlying immune responses. Its significant impact is underscored by its Scopus rankings, where it is placed in the top 15% of journals covering immunology and microbiology. The journal does not currently operate under an Open Access model, yet offers a robust platform for sharing essential findings that contribute to advancements in clinical immunology. As a resource for researchers, professionals, and students, the JOURNAL OF CLINICAL IMMUNOLOGY is pivotal in fostering dialogue and disseminating knowledge that enhances our understanding of immune-related diseases.

HAEMATOLOGICA

Leading the Way in Hematological Innovation
Publisher: FERRATA STORTI FOUNDATIONISSN: 0390-6078Frequency: 12 issues/year

HAEMATOLOGICA, published by FERRATA STORTI FOUNDATION, is a prestigious journal in the field of hematology, recognized for its high impact and contribution to advancing research in this critical area of medicine. With an impressive Q1 ranking in the 2023 category of Hematology and a notable Scopus rank of #12 out of 137, the journal serves as an essential platform for disseminating innovative studies, clinical trials, and comprehensive reviews from 1947 to 2024. Based in Italy, with a commitment to quality and academic integrity, HAEMATOLOGICA fosters collaboration among researchers, practitioners, and students interested in the latest developments and methodologies within hematological science. Although it does not offer open access, the journal ensures that valuable insights are accessible through institutional subscriptions, emphasizing its role in shaping the future of hematologic research.

Journal of Hematology

Connecting Scholars, Enhancing Practice
Publisher: ELMER PRESS INCISSN: 1927-1212Frequency: 4 issues/year

The Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.

Mediterranean Journal of Hematology and Infectious Diseases

Unlocking insights in hematology and infectious diseases for global health.
Publisher: MATTIOLI 1885ISSN: Frequency: 1 issue/year

Mediterranean Journal of Hematology and Infectious Diseases is a distinguished open access journal published by MATTIOLI 1885, dedicated to advancing the field of hematology and infectious diseases. Since its inception in 2009, the journal has provided a platform for researchers and practitioners to disseminate innovative findings, foster scholarly discourse, and enhance our understanding of these critical medical disciplines. With an impact factor reflecting its scholarly influence, it is recognized in the Q3 quartile for both Hematology and Infectious Diseases categories as of 2023. The journal's commitment to open access ensures that high-quality research is accessible to a global audience, contributing to the improvement of clinical practices and public health. Located in Fidenza, Italy, the journal continues to support converged research efforts from 2010 to 2024, making it an essential resource for academics, clinicians, and students in the medical community.

Blood Science

Unveiling Insights in Blood Health and Disorders
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 2543-6368Frequency:

Blood Science is a distinguished peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamic field of hematology. Since its inception, the journal has aimed to disseminate high-quality research and innovative findings that contribute to our understanding of blood-related health issues. With the ISSN 2543-6368, it offers a platform for academic discussions and breakthroughs in various subfields including hematopathology, blood disorders, and transfusion medicine. As of 2023, Blood Science is ranked in the third quartile (Q3) within the hematology category, indicating a burgeoning influence among its peers, with a Scopus rank of #101 out of 137 journals, placing it in the 26th percentile. Although it is not an open-access journal, it provides essential insights and valuable data for researchers, healthcare professionals, and students alike, enhancing the collective knowledge and practices in hematology. With a publication period spanning from 2019 to 2024, Blood Science remains committed to fostering the advancement of blood science research and enhancing patient care methodologies.